Debra Foster

Debra Foster began her professional career as a Registered Nurse specializing in adult critical care. Shortly thereafter Debra joined the critical care clinical research team at Toronto General Hospital and became the project lead for a multi-natinal, multi-center clinical trial, the MEDIC study. The data was used for a successful 510k de novo submission to the FDA for the Endotoxin Activity Assay (EAA), notably the first IVD in the field of sepsis. Debra went on to follow the device to its commercial partner, where she was appointed Vice President of Clinical Development in 2011, and in 2021 became a clinical consultant of Spectral Medical. Debra has led the EUPHRATES and TIGRIS clinical trials, among many others, for a device to treat patients with endotoxemic septic shock. Debra has co-authored over 50 articles and lectured for academic and industry audiences worldwide on the topics of sepsis and clinical trials for sepsis.